AccurKardia – a medical AI software company delivering clinical-grade ECG interpretation software – recently announced the final closing and completion of its $2.7 million seed funding. The investors include the Popular Impact Fund, an early-stage investment vehicle from Popular Inc. (NYSE: BPOP) alongside other private investors. This funding milestone marks a significant step towards AccurKardia’s goal of improving patients’ outcomes and saving millions of lives regardless of geography.
The company was selected to join Cohort 3 of Mayo Clinic Platform_Accelerate, which is a program that provides access to Mayo Clinic’s rich, de-identified data sets, validation frameworks, clinical workflow planning, and mentorship. Since March 2023, AccurKardia has been leveraging these assets to accelerate its R&D and clinical validation work.
KEY QUOTES:
“Given that cardiovascular disease continues to be the leading cause of death worldwide, affecting millions of people, this funding round is key to continuing our journey to bring this technology to market, continue our validation efforts and collaborate with leading cardiology monitoring providers.”
– Juan C. Jiménez, CEO of AccurKardia
“With advances in AI, edge compute capabilities and ubiquitous connectivity, a perfect storm is brewing to deliver planetary-scale tech-enabled healthcare. Our team is primed to develop groundbreaking, life-changing software to interact with clinical and consumer wearables.”
— Sadeq Ali, Co-founder, CPO & CTO of AccurKardia
“At Cooley we love to partner with companies working on breakthrough technologies. We’re thankful to the AccurKardia team for trusting us with their work and are super excited about what they are doing in the tech healthcare space.”
— Cooley Partner Craig Jacoby – who leads the team at Cooley with senior associate Andres Medina-Jordan
